Agreement on industry user fees may force the agency to scale back its intramural program, which critics say is fragmented.
CORPORATE BENEFIT: FDA’s Bernard A. Schwetz contends that the agency’s research program provides direct advantages to industry.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!